ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...
This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...
The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a...
A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...
HPTN 083 is a study being done to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for...
